{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:47:22Z","timestamp":1785448042075,"version":"3.56.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.rmed.2020.106080","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T12:44:01Z","timestamp":1593780241000},"page":"106080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis"],"prefix":"10.1016","volume":"171","author":[{"given":"Diego","family":"Bagnasco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Brussino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bonavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Calzolari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Caminati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"D'Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"De Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiano","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Imeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Di Bona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gilardenghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manlio","family":"Milanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Riccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Rolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierachille","family":"Santus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianenrico","family":"Senna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Passalacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2020.106080_bib1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S2213-2600(16)30187-4","article-title":"Asthma transition from childhood into adulthood","volume":"5","author":"Fuchs","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2020.106080_bib2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3389\/fped.2019.00246","article-title":"Epidemiology of asthma in children and adults","volume":"7","author":"Dharmage","year":"2019","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.rmed.2020.106080_bib3","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2500\/aap.2015.36.3908","article-title":"Severe asthma: epidemiology, burden of illness, and heterogeneity","volume":"36","author":"Lang","year":"2015","journal-title":"Allergy Asthma Proc."},{"key":"10.1016\/j.rmed.2020.106080_bib4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2020.106080_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/ACI.0000000000000493","article-title":"Strategies to reduce corticosteroid-related adverse events in asthma","volume":"19","author":"Heffler","year":"2019","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2020.106080_bib6","doi-asserted-by":"crossref","first-page":"100007","DOI":"10.1016\/j.waojou.2018.12.001","article-title":"Shadow cost of oral corticosteroids-related adverse events: a pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry","volume":"12","author":"Canonica","year":"2019","journal-title":"World Allergy Organ J."},{"key":"10.1016\/j.rmed.2020.106080_bib7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/17425255.2019.1568409","article-title":"Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment","volume":"15","author":"Bagnasco","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.rmed.2020.106080_bib8","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/14740338.2016.1186641","article-title":"The safety of monoclonal antibodies in asthma","volume":"15","author":"Passalacqua","year":"2016","journal-title":"Expert Opin. Drug. Saf."},{"key":"10.1016\/j.rmed.2020.106080_bib9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40264-017-0522-5","article-title":"Targeting interleukin-5 or interleukin-5R\u03b1: safety considerations","volume":"40","author":"Bagnasco","year":"2017","journal-title":"Drug Saf."},{"key":"10.1016\/j.rmed.2020.106080_bib10","doi-asserted-by":"crossref","first-page":"5698212","DOI":"10.1155\/2018\/5698212","article-title":"Anti-IL-5 and IL-5Ra: efficacy and safety of new therapeutic strategies in severe uncontrolled asthma","volume":"2018","author":"Bagnasco","year":"2018","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.rmed.2020.106080_bib11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12931-019-1138-3","article-title":"Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis","volume":"20","author":"Edris","year":"2019","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2020.106080_bib12","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/alr.22214","article-title":"Highlights of eosinophilic chronic rhinosinusitis with nasal polyps in definition, prognosis, and advancement","volume":"8","author":"Lou","year":"2018","journal-title":"Int. Forum Allergy Rhinol."},{"key":"10.1016\/j.rmed.2020.106080_bib13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/alr.21994","article-title":"Role of tissue eosinophils in chronic rhinosinusitis\u2013associated olfactory loss","volume":"7","author":"Hauser","year":"2017","journal-title":"Int. Forum Allergy Rhinol."},{"key":"10.1016\/j.rmed.2020.106080_bib14","first-page":"45","article-title":"Nasal polyps in patients with asthma: prevalence, impact, and management challenges","volume":"9","author":"Langdon","year":"2016","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.rmed.2020.106080_bib15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jaci.2010.11.037","article-title":"Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome","volume":"127","author":"L\u00f6tvall","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2020.106080_bib16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jaip.2016.05.004","article-title":"Phenotypes and emerging endotypes of chronic rhinosinusitis","volume":"4","author":"Bachert","year":"2016","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"10","key":"10.1016\/j.rmed.2020.106080_bib17","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/j.1398-9995.2011.02637.x","article-title":"The association between bacterial colonization and inflammatory pattern in Chinese chronic rhinosinusitis patients with nasal polyps","volume":"66","author":"Ba","year":"2011","journal-title":"Allergy Eur. J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2020.106080_bib18","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2020.106080_bib19","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.anai.2018.01.030","article-title":"Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma","volume":"120","author":"Chipps","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.rmed.2020.106080_bib20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40413-018-0210-7","article-title":"The North-Western Italian experience with anti IL-5 therapy and comparison with regulatory trials","volume":"11","author":"Bagnasco","year":"2018","journal-title":"World Allergy Organ J."},{"issue":"9","key":"10.1016\/j.rmed.2020.106080_bib21","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/lary.27852","article-title":"Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps","volume":"129","author":"Bhattacharyya","year":"2019","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1016\/j.rmed.2020.106080_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhino12.000","article-title":"Epos 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists","volume":"50","author":"Fokkens","year":"2012","journal-title":"Rhinology"},{"issue":"12","key":"10.1016\/j.rmed.2020.106080_bib23","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/all.13875","article-title":"EUFOREA consensus on biologics for CRSwNP with or without asthma","volume":"74","author":"Fokkens","year":"2019","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.rmed.2020.106080_bib24","first-page":"CD013513","article-title":"Biologics for chronic rhinosinusitis","volume":"2","author":"Chong","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.rmed.2020.106080_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.rmed.2020.106080_bib26","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.rmed.2020.106080_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"issue":"10209","key":"10.1016\/j.rmed.2020.106080_bib28","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.rmed.2020.106080_bib29","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jclinepi.2008.12.011","article-title":"A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers","volume":"62","author":"Thorpe","year":"2009","journal-title":"J. Clin. Epidemiol."},{"issue":"4","key":"10.1016\/j.rmed.2020.106080_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2009.06.053","article-title":"The minimally important difference of the Asthma Control Test","volume":"124","author":"Schatz","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"issue":"156","key":"10.1016\/j.rmed.2020.106080_bib31","doi-asserted-by":"crossref","first-page":"190137","DOI":"10.1183\/16000617.0137-2019","article-title":"Minimal clinically important difference for asthma endpoints: an expert consensus report","volume":"29","author":"Bonini","year":"2020","journal-title":"Eur. Respir. Rev."},{"issue":"8","key":"10.1016\/j.rmed.2020.106080_bib32","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/lary.25318","article-title":"The predictive value of the preoperative Sinonasal outcome test-22 score in patients undergoing endoscopic sinus surgery for chronic rhinosinusitis","volume":"125","author":"Hopkins","year":"2015","journal-title":"Laryngoscope"},{"key":"10.1016\/j.rmed.2020.106080_bib33","doi-asserted-by":"crossref","first-page":"101836","DOI":"10.1016\/j.pupt.2019.101836","article-title":"One year of mepolizumab. Efficacy and safety in real-life in Italy","volume":"58","author":"Bagnasco","year":"2019","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.rmed.2020.106080_bib34","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1080\/1744666X.2019.1653758","article-title":"Real-life studies of biologics used in asthma patients: key differences and similarities to trials","volume":"15","author":"Heffler","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"10056","key":"10.1016\/j.rmed.2020.106080_bib35","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"10056","key":"10.1016\/j.rmed.2020.106080_bib36","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.rmed.2020.106080_bib37","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3390\/medicina55070336","article-title":"Rapid effect of benralizumab for hypereosinophilia in a case of severe asthma with eosinophilic chronic rhinosinusitis","volume":"55","author":"Tsurumaki","year":"2019","journal-title":"Medicina (Kaunas)."},{"issue":"5","key":"10.1016\/j.rmed.2020.106080_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2018.01.030","article-title":"Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma","volume":"120","author":"Chipps","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"8","key":"10.1016\/j.rmed.2020.106080_bib39","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/0003489415576181","article-title":"Altered quality of life and psychological health (SCL-90-R) in patients with chronic rhinosinusitis with nasal polyps","volume":"124","author":"Chung","year":"2015","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"10.1016\/j.rmed.2020.106080_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12948-019-0106-2","article-title":"Recovery of smell sense loss by mepolizumab in a patient allergic to dermatophagoides and affected by chronic rhinosinusitis with nasal polyps","volume":"17","author":"Cavaliere","year":"2019","journal-title":"Clin. Mol. Allergy"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611120302201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611120302201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:08:29Z","timestamp":1760616509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611120302201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":40,"alternative-id":["S0954611120302201"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2020.106080","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2020.106080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106080"}}